Nasdaq ctxr.

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is not the most popular stock in this group but hedge fund interest is still above average. Our overall hedge fund sentiment score for CTXR is 59.2.CRANFORD, N.J., May 12, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and ...Citius Pharmaceuticals ( NASDAQ: CTXR) announced an agreement with the special purpose acquisition company (SPAC), TenX Keane Acquisition ( NASDAQ: TENK ), on Tuesday to merge its oncology unit ...Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care ...2,065.70 -1.40(-0.07%) Advertisement Citius Pharmaceuticals, Inc. (CTXR) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 0.7680 +0.0027 (+0.35%) At close: 04:00PM EST 0.7680...

In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Citius Pharmaceuticals (CTXR - Research Report), wi... In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy ratin...

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on ...

Citius Pharmaceuticals (NASDAQ:CTXR) inks securities purchase agreements with certain investors to raise ~$20M through the issuance of ~15.5M shares of common stock and warrants to purchase up to ...Track Citius Pharmaceuticals Inc (CTXR) Stock Price, Quote, latest community messages, chart, news and other stock related information.CRANFORD, N.J., Nov. 21, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first ...CRANFORD, N.J., Oct. 31, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that preclinical research on LYMPHIR ("denileukin diftitox" or ...

Citius Pharmaceuticals, Inc. Common Stock (CTXR) Nasdaq Listed. CLOSED AT 4:00 PM ET ON Jun 23, 2022. DATA AS OF Jun 23, 2022 7:05 PM ET - AFTER HOURS. 0. Add to Watchlist. Add to Portfolio.

Late-stage biopharmaceuticals company Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) ... CTXR's cash balance as of March 2022 stood at $55.8 million down 14.68% from the quarter ending December 31 ...

CRANFORD, N.J., April 24, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and ...The U.S. Food and Drug Administration (FDA) accepted for review Citius Pharmaceuticals' ( NASDAQ: CTXR) application seeking approval of denileukin diftitox (I/ONTAK or E7777) to treat patients ...Nov 29, 2023 · A high-level overview of Citius Pharmaceuticals, Inc. (CTXR) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Get the latest Citius Pharmaceuticals, Inc. (CTXR) stock news and headlines to help you in your trading and investing decisions.1 Wall Street research analysts have issued 1 year target prices for Citius Pharmaceuticals' stock. Their CTXR share price targets range from $4.00 to $4.00. On average, they anticipate the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 415.9% from the stock's current price.Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) gained 17.5% to close at $3.23 on above-average volume. Traders circulated a Seeking Alpha report titled "Citius: Halt For Superiority On The Horizon ...Citius Pharmaceuticals (NASDAQ: CTXR) stock is on the rise Friday despite a lack of news about the company today. The jump in price for CTXR stock comes alongside an increase in trading. As of ...

Nov 29, 2023 · A high-level overview of Citius Pharmaceuticals, Inc. (CTXR) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. CRANFORD, N.J., June 13, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and ...Find the latest SEC Filings data for Citius Pharmaceuticals, Inc. Common Stock (CTXR) at Nasdaq.com.Oct 24, 2023 · Citius Pharmaceuticals ( NASDAQ: CTXR) announced an agreement with the special purpose acquisition company (SPAC), TenX Keane Acquisition ( NASDAQ: TENK ), on Tuesday to merge its oncology unit ... Market Sentiment Around Loss-Making Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) (Simply Wall St.) Nov-05-21 09:15AM. Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls. (PR Newswire) Oct-25-21 09:15AM.If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...Market Activity. Funds + ETFs. Indexes. Currencies. Real-Time Quotes. After-Hours Quotes. Pre-Market Quotes. Nasdaq-100. News + Insights.

CTXR Latest Pre Market Trades. Select time range to see more trades: Last 100 Trades. Pre-Market Time (ET) Pre-Market Price. Pre-Market Share Volume. 09:29:10. $0.9199. 8.

Citius Pharmaceuticals Inc (NASDAQ:CTXR)’s traded shares stood at 0.35 million during the last session, with the company’s beta value hitting 1.42. At the close of trading, the stock’s price was $0.78, to imply an increase of 0.27% or $0.01 in intraday trading. The CTXR share’s 52-week high ...CRANFORD, N.J., Dec. 6, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and ...A high-level overview of Citius Pharmaceuticals, Inc. (CTXR) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.May 12, 2023 · Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care ... With the business potentially at an important milestone, we thought we'd take a closer look at Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) future prospects. Citius Pharmaceuticals, Inc., a ...2,065.70 -1.40(-0.07%) Advertisement Citius Pharmaceuticals, Inc. (CTXR) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 0.7680 +0.0027 (+0.35%) At close: 04:00PM EST 0.7680... Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing first-in-class critical care products, and TenX Keane ...Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a late-stage biopharmaceutical company focused on the development and commercialization of first …Aug 8, 2022 · Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Citius Pharmaceuticals, Inc., a ... Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior ...

With the business potentially at an important milestone, we thought we'd take a closer look at Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) future prospects. Citius Pharmaceuticals, Inc., a ...

May 4, 2023 · CRANFORD, N.J., May 4, 2023 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and ...

Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. Close Trending Tickers barOTC:ZENO NASDAQ:CTXR Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is a specialty pharmaceutical company focused on the development and commercialization of proprietary formulations of already-approved drugs which target large and growing markets. By reformulating, patenting and expanding the indicated uses of drugs that have …CRANFORD, N.J., Oct. 1, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and ...Shares of Citius Pharmaceuticals ( CTXR 2.84%), a clinical-stage biopharmaceutical company, are getting beaten down today after the company released disappointing news regarding its lead candidate ...Mar 27, 2023 · Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is possibly approaching a major achievement in its business, so we would like to shine some light on the company.Citius Pharmaceuticals, Inc., a late ... Nov 11, 2021 · Citius Pharmaceuticals' cash burn of US$22m is about 8.3% of its US$264m market capitalisation. Given that is a rather small percentage, it would probably be really easy for the company to fund ... CRANFORD, N.J., Oct. 13, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it will host a webcast on October 20, 2021 at 8:30 a.m ...CRANFORD, N.J., June 15, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell …Oct 24, 2023 · Health Care Sector Update for 10/24/2023: LIAN, NKGN, MEDP, CTXR October 24, 2023 — 03:50 pm EDT. ... which will be listed on Nasdaq. Citius Pharmaceuticals gained 16%. ... Mar 1, 2023 · Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a Cranford, New Jersey based late-stage drug concern focused on the development of therapies that are typically reformulations of previously approved ... Citius Pharmaceuticals Inc (NASDAQ:CTXR) · Five Year Financial Summary · Total Revenue · Cash & Short Term Investments · Cash From Operations.

Get the latest Citius Pharmaceuticals, Inc. (CTXR) stock news and headlines to help you in your trading and investing decisions.At the end of Q2 2023, CTXR held $33.3 million in cash and equivalents, with total current assets reaching $41.1 million. This was set against a net loss of $8.5 million. They've actually trimmed ...Viatris (NASDAQ:VTRS) announced that the U.S. District Court for the District of Kansas ruled, in substantial part, in Mylan's favor on the company's summary judgment motion in a class action ...Instagram:https://instagram. computers tradingmanage portfoliovanguard high dividend yield etf dividendyall etf Dec 1, 2023 · Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and unique prescription products. Why Invest 5 Diversified Pipeline Candidates best forex copy trade servicepros and cons of cigna health insurance The Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st... b reit Find the latest Insider Activity data for Citius Pharmaceuticals, Inc. Common Stock (CTXR) at Nasdaq.com. Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Number of Hedge Fund Holders: 3. Citrus Pharmaceuticals is one of the best penny stocks to buy now. The stock is listed on the NASDAQ. The company is ...Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care ...